raltitrexed + oxaliplatin

Raltitrexed + oxaliplatin is a combination chemotherapy regimen administered via hepatic arterial infusion (HAI) for the treatment of unresectable colorectal cancer liver metastases. This specific protocol was evaluated by the Centre Georges François Leclerc in the HEARTO Phase II clinical trial. Oxaliplatin is a platinum-based antineoplastic agent that functions by forming inter- and intra-strand DNA crosslinks, thereby inhibiting DNA replication and transcription. Raltitrexed is a quinazoline folate analogue that acts as a potent and specific inhibitor of thymidylate synthase (TS), leading to DNA fragmentation and cell death. The HAI administration route is designed to maximize drug concentration within the hepatic tumors while minimizing systemic exposure and toxicity, particularly for patients who have failed conventional intravenous chemotherapy.

Other names

HAI raltitrexed and oxaliplatinraltitrexed and oxaliplatin